<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02978950</url>
  </required_header>
  <id_info>
    <org_study_id>1050048</org_study_id>
    <nct_id>NCT02978950</nct_id>
  </id_info>
  <brief_title>SToP: Venous Thromboembolism Screening in the Trauma Population</brief_title>
  <acronym>SToP</acronym>
  <official_title>SToP: Venous Thromboembolism Screening in the Trauma Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intermountain Health Care, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intermountain Health Care, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized vanguard trial of trauma patients admitted to the trauma
      surgery service at Intermountain Medical Center who are deemed to be at high risk for venous
      thromboembolism. Once identified and enrolled, subjects will be randomized to receive
      bilateral lower extremity duplex ultrasound surveillance versus no surveillance. The study
      will compare the two groups with regard to deep vein thrombosis, pulmonary embolism, and
      major and clinically relevant bleeding episode rates, both during the index hospitalization
      and at 90 days post-discharge.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 20, 2017</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Asymptomatic lower extremity DVT</measure>
    <time_frame>during index hospitalization, up to 2 weeks</time_frame>
    <description>any DVT found in the lower extremity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptomatic DVT propagation from calf veins to proximal veins</measure>
    <time_frame>14 days from hospital discharge</time_frame>
    <description>calf vein clot that moves to popliteal vein or higher</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic/fatal pulmonary embolism</measure>
    <time_frame>90 days from hospital discharge</time_frame>
    <description>any pulmonary embolism diagnosed by computed tomography angiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major and clinically relevant bleeding episodes</measure>
    <time_frame>during index hospitalization, up to 2 weeks</time_frame>
    <description>as defined by the International Society of Thrombosis and Hemostasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite outcome of proximal DVT plus major and clinically relevant bleeding episodes</measure>
    <time_frame>during index hospitalization, up to 2 weeks</time_frame>
    <description>additive outcome of above knee thrombosis plus major and clinically relevant bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic DVT</measure>
    <time_frame>90 days</time_frame>
    <description>any lower extremity thrombosis that causes clinical symptoms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Venous Thromboembolism</condition>
  <condition>Deep Vein Thrombosis</condition>
  <condition>Trauma, Multiple</condition>
  <arm_group>
    <arm_group_label>Surveillance arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bilateral duplex ultrasound surveillance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No surveillance arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>no duplex ultrasound surveillance</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Duplex ultrasound surveillance</intervention_name>
    <description>bilateral lower extremity venous duplex</description>
    <arm_group_label>Surveillance arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No ultrasound surveillance</intervention_name>
    <description>will have daily exam and history as per normal clinical routine</description>
    <arm_group_label>No surveillance arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Inpatient status on Intermountain Medical Center (IMC) trauma surgery service,
             admitted within 24 hours of injury.

          2. Age â‰¥18 at the time of injury

          3. Meets the definition of high-risk for VTE according to current IMC trauma service
             guidelines

        Exclusion Criteria:

          1. Patient age &lt;18 years at the time of admission to the hospital

          2. Pregnancy

          3. Prisoners

          4. Patients with a life expectancy of less than 30 days

          5. Patients with a known hypercoagulable state including:

               -  Factor V Leiden

               -  Protein C and S deficiencies

               -  Dysfibrogenemia of any sort

               -  Active cancer

               -  Antiphospholipid antibody syndrome

               -  History of DVT or PE within past 6 months

               -  Myeloproliferative disorders

          6. Patients on therapeutic anticoagulation who do not have their agent held upon
             admission to the hospital.

          7. Patient elects to opt-out of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah Majercik, MD,MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Intermountain Health Care, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brent Armbruster</last_name>
    <phone>801-507-4605</phone>
    <email>brent.armbruster@imail.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Valerie Aston, MBA, RT</last_name>
    <phone>801-507-4606</phone>
    <email>Valerie.Aston@imail.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Intermountain Medical Center</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie Aston, MBA, RT</last_name>
      <phone>801-507-4606</phone>
      <email>Valerie.Aston@imail.org</email>
    </contact>
    <contact_backup>
      <last_name>Brent Armbruster</last_name>
      <phone>801-507-4605</phone>
      <email>Brent.Armbruster@imail.org</email>
    </contact_backup>
    <investigator>
      <last_name>Annika Bickford, PA-C</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joseph Bledsoe, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Stevens, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tom White, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Don VanBoerum, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steve Granger, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Scott Stevens, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Scott Woller, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>C. Greg Elliott, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2016</study_first_submitted>
  <study_first_submitted_qc>November 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2016</study_first_posted>
  <last_update_submitted>August 15, 2017</last_update_submitted>
  <last_update_submitted_qc>August 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>duplex ultrasound</keyword>
  <keyword>trauma</keyword>
  <keyword>venous thromboembolism</keyword>
  <keyword>prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
    <mesh_term>Multiple Trauma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

